UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2022

or

o Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from              to

Commission File Number: 001-40361

AGILITI, INC.

(Exact name of registrant as specified in its charter)

Delaware	83-1608463
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

11095 Viking Drive

Eden Prairie, Minnesota 55344

(Address of principal executive offices, including zip code)

(952) 893-3200

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.0001	AGTI	The New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	x	Smaller reporting company	o
		Emerging growth company	o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o   No x

Number of shares of common stock outstanding as of October 31, 2022: 133,337,793

Agiliti, Inc. and Subsidiaries

Table of Contents

		Page
PART I - FINANCIAL INFORMATION		1
ITEM 1.	Consolidated Financial Statements (unaudited)	1
	Consolidated Balance Sheets —September 30, 2022 and December 31, 2021	1
	Consolidated Statements of Operations—Three and nine months ended September 30, 2022 and 2021	2
	Consolidated Statements of Comprehensive Income —Three and nine months ended September 30, 2022 and 2021	3
	Consolidated Statements of Equity — Three and nine months ended September 30, 2022 and 2021	4
	Consolidated Statements of Cash Flows — Nine months ended September 30, 2022 and 2021	6
	Condensed Notes to Consolidated Financial Statements	7
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	29
ITEM 4.	Controls and Procedures	29
PART II - OTHER INFORMATION		29
ITEM 1.	Legal Proceedings	29
ITEM 1A.	Risk Factors	30
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30
ITEM 6.	Exhibits	31
Signatures		32

PART I - FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements — Unaudited

Agiliti, Inc. and Subsidiaries

Consolidated Balance Sheets

(in thousands, except share and per share information)

(unaudited)

	September 30, 2022		December 31, 2021
Assets
Current assets:
Cash and cash equivalents	$	32,211	$	74,325
Accounts receivable, less allowance for credit losses of $3,496 and $2,902	203,087		209,308
Inventories	60,987		55,307
Prepaid expenses	21,503		18,549
Other current assets	13,003		395
Total current assets	330,791		357,884
Property and equipment, net	253,639		258,370
Goodwill	1,218,329		1,213,121
Operating lease right-of-use assets	82,838		80,676
Other intangibles, net	508,769		573,159
Other	23,295		32,537
Total assets	$	2,417,661	$	2,515,747
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	17,642	$	17,534
Current portion of operating lease liability	23,438		22,826
Current portion of obligation under tax receivable agreement	29,824		29,187
Accounts payable	59,094		53,851
Accrued compensation	31,867		47,951
Accrued interest	3,889		3,473
Deferred revenue	9,279		5,808
Other accrued expenses	25,883		27,900
Total current liabilities	200,916		208,530
Long-term debt, less current portion	1,050,288		1,174,968
Obligation under tax receivable agreement, pension and other long-term liabilities	17,036		29,629
Operating lease liability, less current portion	70,259		63,241
Deferred income taxes, net	142,676		143,307
Commitments and contingencies (Note 11)
Equity:
Common stock, $0.0001 par value; 500,000,000 shares authorized; 133,330,184 and 130,950,061 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	13		13
Additional paid-in capital	944,477		938,888
Accumulated deficit	(17,645)		(44,486)
Accumulated other comprehensive income	9,490		1,537
Total Agiliti, Inc. and Subsidiaries equity	936,335		895,952
Noncontrolling interest	151		120
Total equity	936,486		896,072
Total liabilities and equity	$	2,417,661	$	2,515,747

The accompanying notes are an integral part of the unaudited consolidated financial statements.

1

Agiliti, Inc. and Subsidiaries

Consolidated Statements of Operations

(in thousands, except share and per share information)

(unaudited)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Revenue	$	271,185	$	262,424	$	839,613	$	748,212
Cost of revenue	169,582		158,990		516,218		444,346
Gross margin	101,603		103,434		323,395		303,866
Selling, general and administrative expense	86,044		75,052		254,303		225,334
Operating income	15,559		28,382		69,092		78,532
Loss on extinguishment of debt	—		—		1,418		10,116
Interest expense	12,531		10,711		34,456		40,444
Tax indemnification expense	11,918		—		11,918		—
Income (loss) before income taxes and noncontrolling interest	(8,890)		17,671		21,300		27,972
Income tax (benefit) expense	(10,879)		7,943		(5,672)		13,832
Consolidated net income	1,989		9,728		26,972		14,140
Net income attributable to noncontrolling interest	38		60		131		117
Net income attributable to Agiliti, Inc. and Subsidiaries	$	1,951	$	9,668	$	26,841	$	14,023
Basic income per share	$	0.01	$	0.07	$	0.20	$	0.12
Diluted income per share	$	0.01	$	0.07	$	0.19	$	0.11
Weighted-average common shares outstanding:
Basic	133,212,218		130,380,551		132,313,218		117,578,750
Diluted	139,062,813		138,490,526		138,242,880		125,515,000

The accompanying notes are an integral part of the unaudited consolidated financial statements.

2

Agiliti, Inc. and Subsidiaries

Consolidated Statements of Comprehensive Income

(in thousands)

(unaudited)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Consolidated net income	$	1,989	$	9,728	$	26,972	$	14,140
Other comprehensive income:
Gain on minimum pension liability, net of tax of $0, $19, $0, and $56	—		54		—		163
Gain (loss) on cash flow hedge, net of tax of $93, $(6), $2,734, and $297	269		(17)		7,953		875
Total other comprehensive income	269		37		7,953		1,038
Comprehensive income	2,258		9,765		34,925		15,178
Comprehensive income attributable to noncontrolling interest	38		60		131		117
Comprehensive income attributable to Agiliti, Inc. and Subsidiaries	$	2,220	$	9,705	$	34,794	$	15,061

The accompanying notes are an integral part of the unaudited consolidated financial statements.

3

Agiliti, Inc. and Subsidiaries

Consolidated Statements of Equity

(in thousands)

(unaudited)

	Common Stock		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Income		Total Agiliti, Inc. and Subsidiaries		Noncontrolling Interests		Total Equity (Deficit)
Balance as of June 30, 2022	$	13	$	938,906	$	(19,596)	$	9,221	$	928,544	$	166	$	928,710
Net income	—		—		1,951		—		1,951		38		1,989
Other comprehensive income	—		—		—		269		269		—		269
Share-based compensation expense	—		4,712		—		—		4,712		—		4,712
Stock options exercised	—		978		—		—		978		—		978
Shares forfeited for taxes	—		(121)		—		—		(121)		—		(121)
Dividend forfeited, net of payable	—		2		—		—		2		—		2
Cash distributions to noncontrolling interests	—		—		—		—		—		(53)		(53)
Balance as of September 30, 2022	$	13	$	944,477	$	(17,645)	$	9,490	$	936,335	$	151	$	936,486
	Common Stock		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Income (Loss)		Total Agiliti, Inc. and Subsidiaries		Noncontrolling Interests		Total Equity (Deficit)
Balance as of June 30, 2021	$	13	$	928,623	$	(64,137)	$	(2,618)	$	861,881	$	118	$	861,999
Net income	—		—		9,668		—		9,668		60		9,728
Other comprehensive income	—		—		—		37		37		—		37
Share-based compensation expense	—		4,235		—		—		4,235		—		4,235
Stock options exercised	—		7		—		—		7		—		7
Dividend forfeited	—		2		—		—		2		—		2
Cash distributions to noncontrolling interests	—		—		—		—		—		(55)		(55)
Balance as of September 30, 2021	$	13	$	932,867	$	(54,469)	$	(2,581)	$	875,830	$	123	$	875,953

4

	Common Stock		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Income		Total Agiliti, Inc. and Subsidiaries		Noncontrolling Interests		Total Equity (Deficit)
Balance as of December 31, 2021	$	13	$	938,888	$	(44,486)	$	1,537	$	895,952	$	120	$	896,072
Net income	—		—		26,841		—		26,841		131		26,972
Other comprehensive income	—		—		—		7,953		7,953		—		7,953
Proceeds from issuance of common stock	—		2,159		—		—		2,159		—		2,159
Share-based compensation expense	—		14,947		—		—		14,947		—		14,947
Stock options exercised	—		2,949		—		—		2,949		—		2,949
Shares forfeited for taxes	—		(14,488)		—		—		(14,488)		—		(14,488)
Dividend forfeited, net of payable	—		22		—		—		22		—		22
Cash distributions to noncontrolling interests	—		—		—		—		—		(100)		(100)
Balance as of September 30, 2022	$	13	$	944,477	$	(17,645)	$	9,490	$	936,335	$	151	$	936,486
	Common Stock		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Income (Loss)		Total Agiliti, Inc. and Subsidiaries		Noncontrolling Interests		Total Equity (Deficit)
Balance as of December 31, 2020	$	10	$	513,902	$	(68,492)	$	(3,619)	$	441,801	$	144	$	441,945
Net income	—		—		14,023		—		14,023		117		14,140
Other comprehensive income	—		—		—		1,038		1,038		—		1,038
Share-based compensation expense	—		9,917		—		—		9,917		—		9,917
Stock options exercised	—		380		—		—		380		—		380
Issuance of common stock	3		412,738		—		—		412,741		—		412,741
Stock issuance costs	—		(4,084)		—		—		(4,084)		—		(4,084)
Dividend forfeited	—		14		—		—		14		—		14
Cash distributions to noncontrolling interests	—		—		—		—		—		(138)		(138)
Balance as of September 30, 2021	$	13	$	932,867	$	(54,469)	$	(2,581)	$	875,830	$	123	$	875,953

The accompanying notes are an integral part of the unaudited consolidated financial statements.

5

Agiliti, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

	Nine Months Ended September 30,
	2022		2021
Cash flows from operating activities:
Consolidated net income	$	26,972	$	14,140
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	65,502		78,249
Amortization	71,254		63,482
Loss on extinguishment of debt	1,418		7,716
Remeasurement of tax receivable agreement	—		4,542
Provision for credit losses	801		1,121
Provision for inventory obsolescence	859		2,539
Non-cash share-based compensation expense	15,066		10,127
Gain on sales and disposals of equipment	(793)		(3,939)
Deferred income taxes	(3,365)		12,040
Changes in operating assets and liabilities:
Accounts receivable	3,420		(30,305)
Inventories	(6,539)		1,241
Other operating assets	(7,566)		(5,392)
Accounts payable	13,123		4,701
Other operating liabilities	(18,251)		(21,849)
Net cash provided by operating activities	161,901		138,413
Cash flows from investing activities:
Medical equipment purchases	(37,494)		(23,912)
Property and office equipment purchases	(20,374)		(15,539)
Proceeds from disposition of property and equipment	2,695		8,187
Acquisitions, net of cash acquired	(3,125)		(450,198)
Net cash used in investing activities	(58,298)		(481,462)
Cash flows from financing activities:
Proceeds under debt arrangements	20,000		233,052
Payments under debt arrangements	(146,173)		(361,770)
Payments of principal under finance lease liability	(6,676)		(6,721)
Payments of deferred financing costs	—		(229)
Payments under tax receivable agreement	—		(748)
Distributions to noncontrolling interests	(100)		(138)
Proceeds from exercise of stock options	2,949		380
Dividend and equity distribution payment	(908)		(926)
Proceeds from issuance of common stock	—		401,441
Stock issuance costs			(4,084)
Shares forfeited for taxes	(14,488)		—
Payments of contingent consideration	(321)		—
Net cash (used in) provided by financing activities	(145,717)		260,257
Net change in cash and cash equivalents	(42,114)		(82,792)
Cash and cash equivalents at the beginning of period	74,325		206,505
Cash and cash equivalents at the end of period	$	32,211	$	123,713
Supplemental cash flow information:
Interest paid	$	30,214	$	40,991
Income taxes paid	13,172		2,647

The accompanying notes are an integral part of the unaudited consolidated financial statements.

6

Agiliti, Inc. and Subsidiaries

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.    Basis of Presentation

Description of Business

Agiliti, Inc. and its consolidated subsidiaries (Federal Street Acquisition Corp (“FSAC”), Agiliti Holdco, Inc. and Agiliti Health, Inc. and subsidiaries (“we”, “our”, “us”, the “Company” or “Agiliti”)) is a nationwide provider of healthcare technology management and service solutions to the United States healthcare industry. Agiliti, Inc. owns 100% of FSAC. FSAC owns 100% of Agiliti Holdco, Inc. Agiliti Holdco, Inc. owns 100% of Agiliti Health, Inc. Agiliti Health, Inc. owns 100% of Agiliti Surgical, Inc., Agiliti Imaging, Inc., Agiliti Surgical Equipment Repair, Inc. and Sizewise Rentals, LLC. Agiliti Health, Inc. and its subsidiaries are the only entities with operations. All other entities have no material assets, liabilities, cash flows or operations other than their investment and ownership of Agiliti Health, Inc. and subsidiaries.

Initial Public Offering

On April 22, 2021, our registration statement on Form S-1 (File No. 333-253947) related to our initial public offering (“IPO”) was declared effective by the SEC, and our common stock began trading on the New York Stock Exchange (“NYSE”) on April 23, 2021. Our IPO closed on April 27, 2021.

Basis of Presentation

The interim consolidated financial statements have been prepared by the Company without audit. Certain disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto in the Company’s Annual report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on March 8, 2022 (“2021 Form 10-K Report”).

The interim consolidated financial statements presented herein as of September 30, 2022, reflect, in the opinion of management, all adjustments necessary for a fair presentation of the financial position, results of operations, comprehensive income, equity and cash flows for the periods presented. These adjustments are all of a normal, recurring nature. The results of operations for any interim period are not necessarily indicative of results for the full year.

We are required to make estimates and assumptions about future events in preparing consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the amounts of assets, liabilities, revenue and expenses at the date of the unaudited consolidated financial statements. While we believe that our past estimates and assumptions have been materially accurate, our current estimates are subject to change if different assumptions as to the outcome of future events are made. We evaluate our estimates and judgments on an ongoing basis and predicate those estimates and judgments on historical experience and on various other factors that we believe to be reasonable under the circumstances. We make adjustments to our assumptions and judgments when facts and circumstances dictate. Since future events and their effects cannot be determined with absolute certainty, actual results may differ from the estimates used in preparing the accompanying unaudited consolidated financial statements.

Income Taxes

Pursuant to the receipt of a Private Letter Ruling from the IRS during the three months ended September 30, 2022, we released a reserve assumed from our Sizewise Acquisition in 2021. The exposure was covered by an indemnification agreement with the seller. The release of the reserve and associated interest and penalties accrual resulted in a $11.9 million tax benefit and indemnification expense for the same amount, which is included in ‘Tax indemnification expense’ on the Consolidated Statements of Operations. The release of the reserve is treated as a significant, unusual item under the provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 740, “Income Taxes”, and Subtopic 740-270, and $11.9 million tax benefit recognized resulted in a significant variation in the customary relationship between income tax expense (benefit) and pre-tax income (loss) for the three and nine months ended September 30, 2022.

7

Significant Accounting Policies and Estimates

The most recent review of estimated useful lives of fixed assets indicated that certain medical equipment had actual lives that were longer than previously estimated. As a result, effective July 1, 2022, we increased the expected useful lives of such medical equipment from four to seven years to five to ten years on a prospective basis. The effect of this change reduced depreciation expense by approximately $3.8 million and increased net income by approximately $2.8 million, or $0.02 per basic and diluted share for the three and nine months ended September 30, 2022.

A description of our significant accounting policies is included in the audited consolidated financial statements. There have been no material changes to these policies for the quarter ended September 30, 2022.

2.    Recent Accounting Pronouncements

Standards Adopted

No recent accounting pronouncements have been issued or adopted since those discussed in the 2021 Form 10-K Report that are of material significance, or have potential material significance, to the Company.

Standards Not Yet Adopted

In October 2021, the FASB issued ASU No. 2021-08 Business Combinations (Topic 805)-Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 improves the accounting for acquired revenue contracts with customers in a business combination. The amendments in this ASU require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted. We will continue to evaluate ASU 2021-08, but do not expect the adoption will have a material impact on our consolidated financial statements.

In September 2020, the FASB issued ASU No. 2020-04 Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The ASU may be applied through December 31, 2022. We will continue to evaluate the phase out of LIBOR but do not expect the adoption will have a material impact on our consolidated financial statements.

3.    Revenue Recognition

Customer arrangements typically have multiple performance obligations to provide equipment solutions, clinical engineering and/or onsite equipment managed services on a per use and/or over time basis. Contractual prices are established within our customer arrangements that are representative of stand-alone selling prices. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. The Company’s performance obligations that are satisfied at a point in time are recognized when the service is performed or equipment is delivered to the customer. For performance obligations satisfied over time, the Company uses a straight-line method to recognize revenue ratably over the contract period, as this coincides with the Company’s performance under the contract.

In the following table, revenue is disaggregated by service solution:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2022		2021		2022		2021
Equipment Solutions	$	103,103	$	77,707	$	331,810	$	232,319
Clinical Engineering	103,639		111,614		310,850		287,860
Onsite Managed Services	64,443		73,103		196,953		228,033
Total revenue	$	271,185	$	262,424	$	839,613	$	748,212

8

The Company capitalizes contract costs incurred in obtaining new contracts. The contract asset included in other long-term assets in the consolidated balance sheets as of September 30, 2022 and December 31, 2021 was $18.1 and $15.9 million, respectively. Capitalized costs are amortized over the expected life of the related contracts, which is estimated to be five years.

The Company had a balance of $9.3 and $5.8 million of deferred revenue as of September 30, 2022 and December 31, 2021, respectively. During the three and nine months ended September 30, 2022, $0.7 and $2.2 million, respectively, of revenue was recognized that was included in deferred revenue at the beginning of the period.

4.    Acquisitions

During the three months ended June 30, 2022, we completed the acquisition of several small surgical equipment repair companies. These business combinations were immaterial in relation to our consolidated balance sheets and statements of operations and as a result, additional purchase accounting disclosures have been omitted.

On October 1, 2021, we completed a stock purchase agreement to purchase all of the outstanding capital stock of Sizewise Rentals, LLC (“Sizewise”), a privately held manufacturer and distributor of specialty patient handling equipment, for a total consideration of approximately $234.8 million (“Sizewise Acquisition”). The results of Sizewise’s operations have been included in the consolidated financial statements since October 1, 2021.

The following summarizes the fair values of assets acquired and liabilities assumed at the date of the Sizewise Acquisition within our consolidated balance sheet as of December 31, 2021:

(in thousands)
Cash	$	9,977
Accounts receivable	31,005
Inventories	27,911
Other current assets	2,968
Property and equipment	59,042
Goodwill	87,867
Operating lease right-of-use assets	16,754
Other intangibles	67,700
Other long-term assets	10,368
Accounts payable	(3,362)
Accrued compensation	(12,576)
Other accrued expenses	(4,525)
Operating lease liability	(16,953)
Other long-term liabilities	(9,924)
Deferred income taxes	(31,470)
Total purchase price	$	234,782

On March 19, 2021, we completed a stock purchase agreement to purchase all of the outstanding capital stock of Northfield Medical, Inc. (“Northfield”), a company specializing in the service and repair of medical equipment and instruments for a total consideration of approximately $472.3 million (“Northfield Acquisition”). The consideration consisted of $461.0 million of cash paid and $11.3 million in issuance of 752,328 shares of common stock. The results of Northfield’s operations have been included in the consolidated financial statements since March 19, 2021. During the year ended December 31, 2021, adjustments affecting the fair values of assets acquired and liabilities assumed decreased accounts receivable $0.2 million, increased goodwill $1.3 million, increased accounts payable $0.1 million, and increased deferred income taxes $1.0 million. All adjustments net to zero.

9

The following summarizes the fair values of assets acquired and liabilities assumed at the date of the Northfield Acquisition within our consolidated balance sheet as of December 31, 2021:

(in thousands)
Cash	$	10,767
Accounts receivable	16,786
Inventories	5,810
Other current assets	502
Property and equipment	11,713
Goodwill	306,678
Operating lease right-of-use assets	4,815
Other intangibles	183,700
Accounts payable	(7,412)
Accrued compensation	(7,948)
Other accrued expenses	(9,620)
Finance lease liability	(2,340)
Operating lease liability	(5,025)
Other long-term liabilities	(837)
Deferred income taxes	(35,324)
Total purchase price	$	472,265

The following unaudited pro forma consolidated results of operations assume the Sizewise and Northfield acquisitions had occurred on January 1, 2021. The unaudited pro forma consolidated financial information should not be relied upon as necessarily being indicative of the historical results that would have been obtained if the acquisitions had actually closed on that date, nor the results that may be obtained in the future:

	Three Months Ended September 30,				Nine Months Ended September 30,
(unaudited, in thousands)	2022		2021		2022		2021
Revenue	$	271,185	$	303,028	$	839,613	$	895,994
Net income attributable to Agiliti, Inc. and Subsidiaries	1,951		10,670		26,841		21,623

Included in the determination of pro forma net income for the three and nine months ended September 30, 2021 are pro forma charges for various purchase accounting adjustments. These pro forma adjustments included depreciation and amortization of assets acquired and interest expense on additional debt to finance the acquisition. Income taxes are provided at the estimated statutory rate. Revenue and net income for the three and nine months ended September 30, 2022 are as reported.

10

5.    Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021 are summarized in the following tables by type of inputs applicable to the fair value measurements:

	Fair Value at September 30, 2022
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Deferred compensation assets	$	2,449	$	—	$	—	$	2,449
Interest rate swap	—		12,780		—		12,780
Total Assets	$	2,449	$	12,780	$	—	$	15,229
Liabilities:
Contingent consideration	$	—	$	—	$	3,649	$	3,649
Obligation under tax receivable agreement	—		—		40,517		40,517
Deferred compensation liabilities	2,449		—		—		2,449
Total Liabilities	$	2,449	$	—	$	44,166	$	46,615

	Fair Value at December 31, 2021
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Deferred compensation assets	$	2,452	$	—	$	—	$	2,452
Interest rate swap	—		2,093		—		2,093
Total Assets	$	2,452	$	2,093	$	—	$	4,545
Liabilities:
Contingent consideration	$	—	$	—	$	500	$	500
Obligation under tax receivable agreement	—		—		39,880		39,880
Deferred compensation liabilities	2,452		—		—		2,452
Total Liabilities	$	2,452	$	—	$	40,380	$	42,832

A description of the inputs used in the valuation of assets and liabilities is summarized as follows:

Level 1 — Inputs represent unadjusted quoted prices for identical assets or liabilities exchanged in active markets.

Level 2 — Inputs include directly or indirectly observable inputs other than Level 1 inputs such as quoted prices for similar assets or liabilities exchanged in active or inactive markets; quoted prices for identical assets or liabilities exchanged in inactive markets; other inputs that are considered in fair value determinations of the assets or liabilities, such as interest rates and yield curves that are observable at commonly quoted intervals, volatilities, prepayment speeds, loss severities, credit risks and default rates; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 — Inputs include unobservable inputs used in the measurement of assets and liabilities. Management is required to use its own assumptions regarding unobservable inputs because there is little, if any, market activity in the assets or liabilities or related observable inputs that can be corroborated at the measurement date. Measurements of non-exchange traded derivative contract assets and liabilities are primarily based on valuation models, discounted cash flow models or other valuation techniques that are believed to be used by market participants. Unobservable inputs require management to make certain projections and assumptions about the information that would be used by market participants in pricing assets or liabilities.

The deferred compensation assets are held in mutual funds. The fair value of the deferred compensation assets and liabilities is based on the quoted market prices for the mutual funds and thus represents a Level 1 fair value measurement.

On January 4, 2019, we entered into a tax receivable agreement (“TRA”) with our former owners. The fair value of the obligation under the TRA was estimated using company specific assumptions that are not observable in the market and thus represents a Level 3 fair value measurement. Management’s estimate of the valuation of the obligation under the TRA

11

is based on a Monte Carlo model which involves the use of projected cash flows of the Company, a discount rate, and historical deferred tax assets subject to the agreement. There were no remeasurement adjustments or payments made under the TRA during the three and nine months ended September 30, 2022. We made a remeasurement adjustment of $4.5 million and payment of $0.7 million during the three and nine months ended September 30, 2021.

In May 2020, we entered into an interest rate swap agreement to manage our interest rate exposure. For additional information on the interest swap agreement, see Note 8, Long-Term Debt. The carrying value of interest rate swap contracts is at fair value, which is determined based on current interest rate and forward interest rates as of the balance sheet date and is classified within Level 2.

In January 2022, a $0.5 million earn-out payment was made to the previous owners of a surgical laser equipment solutions company, in which we acquired assets on December 11, 2020, based on achievement of certain revenue results. During the three months ended June 30, 2022, we completed the acquisition of several small surgical equipment repair companies and as a result, have accrued $3.6 million as of September 30, 2022 for future earn-out payments contingent upon achievement of certain revenue results.

Fair Value of Other Financial Instruments

The Company considers that the carrying amount of financial instruments, including accounts receivable, accounts payable and accrued liabilities approximates fair value due to their short maturities. The fair value of our outstanding First Lien Term Loan (as defined in Note 8, Long-Term Debt) as of September 30, 2022 and December 31, 2021, is based on the quoted market price for the same or similar issues of debt, which represents a Level 2 fair value measurement, is approximately:

	September 30, 2022				December 31, 2021
(in thousands)	Carrying Value		Fair Value		Carrying Value		Fair Value
First Lien Term Loan (1)	$	1,045,443	$	1,027,833	$	1,167,649	$	1,174,871

________________________

(1) The carrying value of the First Lien Term Loan is net of unamortized deferred financing costs of $8.6 and $10.4 million and unamortized debt discount of $2.8 and $5.0 million as of September 30, 2022 and December 31, 2021, respectively.

6.    Selected Financial Statement Information

Property and Equipment

Our Property and Equipment is grouped into Medical Equipment and Property and Office Equipment. Depreciation of medical equipment is provided on the straight-line method over the equipment’s estimated useful life, generally five to ten years. The cost and accumulated depreciation of medical equipment retired or sold is eliminated from their respective accounts and the resulting gain or loss is recorded in cost of revenue in the period the asset is retired or sold. Property and office equipment includes property, leasehold improvements and office equipment. Depreciation and amortization of property and office equipment is provided on the straight-line method over the lesser of the remaining useful life or lease term for leasehold improvements and three to ten years for office equipment. The cost and accumulated depreciation or amortization of property and equipment retired or sold is eliminated from their respective accounts and the resulting gain or loss is recorded in selling, general and administrative expense in the period the asset is retired or sold.

12

(in thousands)	September 30, 2022		December 31, 2021
Medical equipment	$	380,107	$	359,284
Less: Accumulated depreciation	(238,073)		(209,516)
Medical equipment, net	142,034		149,768
Leasehold improvements	48,413		39,026
Office equipment and vehicles	153,721		135,643
	202,134		174,669
Less: Accumulated depreciation	(90,529)		(66,067)
Property and office equipment, net	111,605		108,602
Total property and equipment, net	$	253,639	$	258,370

Depreciation expense recognized during the three months ended September 30, 2022 and 2021 was $19.1 and $25.4 million, respectively. Depreciation expense recognized during the nine months ended September 30, 2022 and 2021 was $65.5 and $78.2 million, respectively.

There were no impairment charges on property and equipment during the three and nine months ended September 30, 2022 and 2021.

Goodwill and Other Intangible Assets

Our goodwill as of September 30, 2022 and December 31, 2021 consists of the following:

(in thousands)
Balance at December 31, 2021	$	1,213,121
Acquisitions	5,208
Balance at September 30, 2022	$	1,218,329

There were no impairment losses recorded on goodwill through September 30, 2022.

Our other intangible assets as of September 30, 2022 and December 31, 2021 consist of the following:

	September 30, 2022
(in thousands)	Gross		Accumulated Amortization		Net
Finite-life intangibles
Customer relationship	$	756,889	$	(255,295)	$	501,594
Non-compete agreements	5,235		(4,835)		400
Trade names	7,806		(2,488)		5,318
Developed technology	2,300		(843)		1,457
Total other intangible assets	$	772,230	$	(263,461)	$	508,769

	December 31, 2021
(in thousands)	Gross		Accumulated Amortization		Net
Finite-life intangibles
Customer relationship	$	756,889	$	(194,312)	$	562,577
Non-compete agreements	14,613		(13,222)		1,391
Trade names	9,179		(2,230)		6,949
Developed technology	2,300		(58)		2,242
Total other intangible assets	$	782,981	$	(209,822)	$	573,159

13

Our other intangible assets are amortized over their estimated economic lives of three to fifteen years. The straight-line method of amortization generally reflects an appropriate allocation of the cost of the intangible assets to earnings in proportion to the amount of economic benefits obtained by the Company in each reporting period. However, for certain of our customer relationships, we use the sum-of-the-years-digits amortization method to more appropriately allocate the cost to earnings in proportion to the estimated amount of economic benefit obtained.

Total amortization expense related to intangible assets was $21.7 and $20.6 million for the three months ended September 30, 2022 and 2021, respectively, and $64.4 and $57.7 million for the nine months ended September 30, 2022 and 2021, respectively. There were no impairment charges during the three and nine months ended September 30, 2022 and 2021 with respect to other intangible assets.

The estimated future amortization expense for identifiable intangible assets during the remainder of 2022 and the next five years is as follows:

(in thousands)
Remainder of 2022	$	21,574
2023	79,108
2024	68,604
2025	62,242
2026	55,870
2027	49,516

Supplementary Cash Flow Information

Supplementary cash flow information is as follows:

	September 30,
(in thousands)	2022		2021
Non-cash activities:
Property and equipment purchases included in accounts payable (at end of period)	$	2,976	$	1,927
Finance lease assets and liability additions	4,104		6,795
Operating lease right-of-use assets and operating lease liability additions	19,580		9,731
Issuance of common stock related to acquisition	—		11,300

7.    Share-Based Compensation

The 2018 Omnibus Incentive Plan (“2018 Plan”) provides for the issuance of 16.7 million nonqualified stock options, restricted stock units and performance restricted stock units to any of the Company’s executives, other key employees and certain non-employee directors. The stock options allow for the purchase of shares of common stock of the Company at prices equal to the stock’s fair market value at the date of grant. Options granted have a ten-year contractual term and vest over one to four years. The restricted stock units vest over one to four years. The performance restricted stock units have both performance and service conditions and certain awards also have market based vesting conditions. The non-market based awards vest over three years upon achievement of established performance targets and a service requirement as defined in the respective award agreements. The market based awards cliff vest at three years with the achievement of the performance goals and completion of the required service period.

The shares issued to a grantee upon the exercise of such grantee’s options will be subject to certain restrictions on transferability as provided in the 2018 Plan. Grantees are subject to non-competition, non-solicitation and confidentiality requirements as set forth in their respective stock option grant agreements. Forfeited options, restricted stock units and performance restricted stock units are available for future issue.

We determine the fair value of stock options using the Black-Scholes option pricing model. The estimated fair value of options, including the effect of estimated forfeitures, is recognized as an expense on a straight-line basis over the options’ expected vesting periods.

14

The fair value of the market based performance restricted stock units is estimated at the grant date using a Monte-Carlo simulation model which included the following assumptions:

Risk-free interest rate	1.65
Expected dividend yield	—	%
Average expected volatility of the peer companies in the S&P Index	52.1	%
Expected volatility of the Company (1)	52.5	%
Expected term	2.83

____________________

(1) Expected volatility of the Company was calculated using a weighted-average of historical data available (0.85 years) and the remaining weight split equally among guideline public companies.

In connection with our IPO, we granted certain of our employees, including our named executive officers, restricted stock units, performance restricted stock units, and stock options under the 2018 Plan with respect to approximately 1.6 million shares of the Company’s common stock.

A total of 2.0 million shares of our common stock are reserved for issuance under our Employee Stock Purchase Plan ("ESPP"). Employees are permitted to purchase the Company’s common stock at 85% of market value at the end of the six-month offering period ending on April 30 and October 31 each year. 0.1 million shares were issued under the ESPP as of September 30, 2022. The Company recognizes share-based compensation expense for the discount received by participating employees. The Company recognized $0.1 and $0.5 million share-based compensation expense for the discount received by participating employees for the three and nine months ended September 30, 2022.

Remaining authorized options, restricted stock units and performance restricted stock units available for future issuance were 7.4 million shares at September 30, 2022.

8.    Long-Term Debt

Long-term debt consists of the following:

(in thousands)	September 30, 2022		December 31, 2021
Revolving Loan	$	—	$	—
First Lien Term Loan	1,056,898		1,183,071
Finance lease liability	23,876		26,621
	1,080,774		1,209,692
Less: unamortized deferred financing costs and debt discount	(12,844)		(17,190)
	1,067,930		1,192,502
Less: Current portion of long-term debt	(17,642)		(17,534)
Total long-term debt	$	1,050,288	$	1,174,968

We are party to a seven-year senior secured delayed draw term loan facility due January 2026 which, as amended, provides an aggregate principal amount of $1.285 billion in borrowing capacity (the “First Lien Term Loan”). We also have access to a senior secured revolving credit facility due January 2026 in an aggregate principal amount of $250 million (the “Revolving Loan”).

During the nine months ended September 30, 2022, we prepaid $119.1 million of the borrowings under the First Lien Term Loan which resulted in a loss on extinguishment of $1.4 million.

Additional information regarding our indebtedness arrangements can be found within the notes to our consolidated financial statements in our most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

Interest Rate Swap. In May 2020, we entered into an interest rate swap agreement for a total notional amount of $500.0 million, which has the effect of converting a portion of our First Lien Term Loan to fixed interest rates. The effective date for the interest rate swap agreement was June 2020 and the expiration date is June 2023.

15

The interest rate swap agreement qualifies for cash flow hedge accounting under ASC Topic 815, “Derivatives and Hedging.” Both at inception and on an on-going basis, we must perform an effectiveness test. The fair value of the interest rate swap agreement at September 30, 2022 was $12.8 million all of which is included in other current assets on our consolidated balance sheet. The change in fair value was recorded as a component of accumulated other comprehensive income on our consolidated balance sheet, net of tax, since the instrument was determined to be an effective hedge at September 30, 2022. We have not recorded any amounts due to ineffectiveness for any periods presented.

As a result of our interest rate swap agreement, we expect the effective interest rate on $350.0 million and $150.0 million of our First Lien Term Loan to be 0.3396% and 0.3290%, respectively, plus the Applicable Margin through June 2023.

We were in compliance with all financial debt covenants for all periods presented.

9.    Leases

We lease facilities under operating lease agreements, which include both monthly and longer-term arrangements. Our finance leases consist primarily of leased vehicles.

The lease assets and liabilities are as follows:

(in thousands)		September 30, 2022		December 31, 2021
Lease Assets	Classification
Operating lease assets	Operating lease right-of-use assets	$	82,838	$	80,676
Finance lease assets	Property and equipment (1)	23,485		26,098
Total leased assets		$	106,323	$	106,774
Lease Liabilities
Current:
Operating	Current portion of operating lease liability	$	23,438	$	22,826
Finance	Current portion of long-term debt	8,244		8,136
Noncurrent:
Operating	Operating lease liability, less current portion	70,259		63,241
Finance	Long-term debt, less current portion	15,632		18,485
Total lease liabilities		$	117,573	$	112,688

____________________

(1) Finance lease assets are recorded net of accumulated depreciation of $27.5 and $20.4 million as of September 30, 2022 and December 31, 2021, respectively.

The lease cost for the three and nine months ended September 30, 2022 and 2021 was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2022		2021		2022		2021
Lease Cost
Finance lease cost:
Amortization of right-of-use assets	$	2,157	$	2,115	$	6,501	$	6,493
Interest on lease liabilities	216		179		599		557
Operating lease cost	7,270		5,074		21,765		14,150
Short-term lease cost	222		239		752		575
Variable lease cost	1,629		1,472		4,739		4,247
Total lease cost	$	11,494	$	9,079	$	34,356	$	26,022

16

The maturity of lease liabilities at September 30, 2022 was as follows:

(in thousands)	Operating Leases		Finance Leases		Total
2022 remaining	$	6,527	$	2,770	$	9,297
2023	24,675		8,072		32,747
2024	21,696		5,275		26,971
2025	17,639		3,453		21,092
2026	13,272		2,277		15,549
Thereafter	15,295		4,316		19,611
Total lease payments	$	99,104	$	26,163	$	125,267
Less: Interest	5,407		2,287		7,694
Present value of lease liabilities	$	93,697	$	23,876	$	117,573

The lease term and discount rate at September 30, 2022 were as follows:

	September 30, 2022
Lease Term and Discount Rate
Weighted-average remaining lease term (years)
Operating leases	5.0
Finance leases	2.2
Weighted-average discount rate
Operating leases	2.3	%
Finance leases	2.2	%

Other information related to cash paid related to lease liabilities and lease assets obtained for the nine months ended September 30, 2022 and 2021 was as follows:

	Nine Months Ended September 30,
(in thousands)	2022		2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for finance leases	$	599	$	557
Operating cash flows for operating leases	19,262		13,362
Financing cash flows for finance leases	6,676		6,721
Lease asset obtained in exchange for new finance lease liabilities	4,104		6,795
Lease asset obtained in exchange for new operating lease liabilities	19,580		9,731

10.    Dividend

In November 2019, the Company declared a $2.23 dividend per share that was paid to holders of common stock and is paid upon vesting to holders of restricted stock units and performance restricted stock units. An immaterial amount of dividends were paid during the three months ended September 30, 2022 and 2021. Dividends paid during both the nine months ended September 30, 2022 and 2021 were $0.9 million.

Dividends payable was $0.3 million as of September 30, 2022, all of which was included in accounts payable, and $1.2 million as of December 31, 2021, of which $0.9 million was included in accounts payable and $0.3 million was included in other long-term liabilities.

17

11.    Commitments and Contingencies

The Company, in the ordinary course of business, is subject to liability claims related to employees and the equipment that it rents and services. Asserted claims are subject to many uncertainties and the outcome of individual matters is not predictable. For certain claims where the loss is probable, a provision is recorded based on the Company’s best estimate. While the ultimate resolution of these actions may have an impact on the Company’s financial results for a particular reporting period, management believes that any such resolution would not have a material adverse effect on the financial position, results of operations or cash flows of the Company and the chance of a negative outcome on outstanding litigation is considered remote.

12.    Related Party Transaction

Since January 2019, we have been controlled by THL Agiliti LLC, an affiliate of Thomas H. Lee Partners, L.P., our principal stockholder. On January 4, 2019, the Company entered into an advisory services agreement (the “Advisory Services Agreement”) with Agiliti Holdco, Inc., Agiliti Health, Inc. and THL Managers VIII, LLC (the “Advisor”). Pursuant to the Advisory Services Agreement, the Advisor provided management, consulting and other advisory services to the Company. In consideration for these services, the Company paid to the Advisor (i) a non-refundable periodic retainer fee in an aggregate amount per fiscal quarter equal to the greater of (a) $375,000 or (b) 1% of the consolidated Adjusted EBITDA (as defined in the Advisory Services Agreement) for the immediately preceding fiscal quarter or such other amount as may be mutually agreed, with the first such payment to be made on April 15, 2019, (ii) fees in amounts to be mutually agreed upon in connection with any financing or refinancing, dividend, recapitalization, acquisition, disposition and spin-off or split-off transaction, (iii) in the case of an initial public offering (“IPO”), in addition to the fees under clauses (i) and (ii), an amount equal to the net present value of the higher periodic fee that would have been payable from the date of such IPO until the scheduled termination date of the Advisory Services Agreement, and (iv) fees for other management, consulting and other advisory services to be discussed in good faith among the parties. The companies also paid expenses incurred by the Advisor, its consultants and certain other parties affiliated with Advisor. Total professional services fees incurred to the Advisor were $0 and $0.6 million for the three and nine months ended September 30, 2021. The Advisory Services Agreement was terminated upon the completion of the IPO. In connection with the termination of the Advisory Services Agreement, we were required to pay to the Advisor a buyout fee of approximately $7.0 million, which was expensed immediately in the second quarter of 2021.

13.    Employee Benefit Plans

Pension plan benefits are to be paid to eligible employees after retirement based primarily on years of credited service and participants’ compensation. The Company uses a December 31 measurement date. Effective December 31, 2002, the Company froze the benefits under the pension plan.

The components of net periodic benefit cost are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2022		2021		2022		2021
Interest cost	$	212	$	196	$	635	$	589
Expected return on plan assets	(285)		(276)		(854)		(830)
Recognized net actuarial loss	—		73		—		219
Net periodic benefit cost	$	(73)	$	(7)	$	(219)	$	(22)

The Company made $0.7 million of contributions to the pension plan during the nine months ended September 30, 2022. The Company does not expect to make any additional contributions for the remainder of 2022.

14.    Income Taxes

For the three and nine months ended September 30, 2022, the Company recorded income tax benefit of $10.9 and $5.7 million, respectively. For the three and nine months ended September 30, 2021, the Company recorded income tax expense of $7.9 and $13.8 million, respectively. The income tax benefit for the three months ended September 30, 2022 was primarily due to the release of the reserve related to the Sizewise Acquisition offset by the tax-effect of pre-tax income from operations. The income tax benefit for the nine months ended September 30, 2022 was primarily due to the release of the reserve related to the Sizewise Acquisition and benefit from stock options and stock compensation offset by the effect of pre-tax income from operations plus addbacks for non-deductible expenses related to executive compensation

18

disallowed under Internal Revenue Code Section 162(m). The income tax expense for the three and nine months ended September 30, 2021 is primarily due to the tax-effect of pre-tax income from operations plus addbacks for non-deductible transaction costs, non-deductible expenses related to executive compensation disallowed under Internal Revenue Code Section 162(m) and the remeasurement of the tax receivable agreement.

During the nine months ended September 30, 2022, gross unrecognized tax benefits decreased by $8.7 million to $1.3 million. Pursuant to the receipt of a Private Letter Ruling from the IRS during the three months ended September 30, 2022, we released the reserve assumed from the Sizewise Acquisition. The exposure was covered by an indemnification agreement with the seller, so the release resulted in a tax benefit and indemnification expense for the same amount. We do not currently expect any additional significant changes in the amount of unrecognized tax benefits during the next twelve months.

We recognize interest and penalties related to unrecognized tax benefits as a component of our income tax provision. We have no accrued interest and penalties as of September 30, 2022 and $3.2 million as of December 31, 2021. The decrease in accrued interest and penalties is due to the reserve release noted above.

During the three months ended September 30, 2022, the Inflation Reduction Act (“IRA”) was signed into law. The IRA introduces a Corporate Alternative Minimum Tax beginning in 2023 and an excise tax on the repurchase of corporate stock starting after January 1, 2023. We do not currently expect the IRA to have a material impact on our financial results. We will continue to monitor and assess the impact the IRA may have on our business and financial results.

15.    Concentration

For the three and nine months ended September 30, 2022, respectively, approximately 10.4% and 10.8% of total revenue related to various contracts with the U.S. Department of Health and Human Services (“HHS”) and the Assistant Secretary of Preparedness and Response (“ASPR”).

On February 28, 2022, the Company entered into a new 12-month sole source agreement (the “Agreement”) with HHS and ASPR to provide comprehensive ventilator and powered air purifying respirator (“PAPR”) systems management and maintenance services in connection with ongoing support and maintenance of the national stockpile. This Agreement replaces the Company’s prior agreements with HHS/ASPR that ran from July 21, 2020, to February 27, 2022, and is comprised of an initial 6-month base term, running from the period of February 28, 2022, to August 27, 2022, with a 6-month option term that will expire February 27, 2023.

The term of the Company’s current Agreement with HHS/ASPR is intended to allow adequate time for the federal government to complete a longer-term agreement for comprehensive ventilator and PAPR systems management and maintenance services without a lapse in critical COVID-19 pandemic response needs. On August 5, 2022, the Company submitted its response to HHS/ASPR’s request for proposal in connection with this five-year agreement and is awaiting next steps in this regard.    

16.    Earnings Per Share

The following is a reconciliation of the basic and diluted number of shares used in computing earnings per share:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Basic weighted average shares outstanding	133,212,218		130,380,551		132,313,218		117,578,750
Net effect of dilutive stock awards based upon the treasury stock method	5,850,595		8,109,975		5,929,662		7,936,250
Dilutive weighted average shares outstanding	139,062,813		138,490,526		138,242,880		125,515,000
Basic earnings per share	$	0.01	$	0.07	$	0.20	$	0.12
Diluted earnings per share	$	0.01	$	0.07	$	0.19	$	0.11
Anti-dilutive share-based awards excluded from the calculation of dilutive earnings per share	9,203		—		9,203		—

19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and with the audited consolidated financial statements and the related notes thereto in the Company’s Annual report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on March 8, 2022 (“2021 Form 10-K Report”). In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. You should review the sections titled “Note Regarding Forward-Looking Statements” for a discussion of forward-looking statements as well as the section titled “Risk Factors” for a discussion of factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis and elsewhere in this Quarterly Report on Form 10-Q and in our 2021 Form 10-K Report.

BUSINESS OVERVIEW

Our Company

Unless otherwise specified, the terms “we”, “our”, “us” and the “Company” refer to Agiliti, Inc. and, where appropriate, its consolidated subsidiaries.

We believe we are one of the leading experts in the manufacturing, management, maintenance and mobilization of mission-critical, regulated, reusable medical devices. We offer healthcare providers a comprehensive suite of medical equipment management and service solutions that help reduce capital and operating expenses, optimize medical equipment utilization, reduce waste, enhance staff productivity and bolster patient safety.

We commenced operations in 1939, originally incorporated in Minnesota in 1954 and reincorporated in Delaware in 2001.

In our more than 80 years of experience ensuring healthcare providers have high-quality, expertly maintained equipment to serve their patients, we’ve established a nationwide operating footprint that supports our offering. This at-scale, local market service and logistics infrastructure positions us to reach customers across the entire healthcare continuum—from individual facilities to the largest and most complex healthcare systems. Our ability to rapidly mobilize, track, repair and redeploy equipment during times of peak need or emergent events has made us a service provider of choice for city, state and the federal government in the management of emergency equipment stockpiles.

Our diverse customer base includes more than 9,000 national, regional and local acute care hospitals, health systems and integrated delivery networks and alternate site providers (such as surgery centers, specialty hospitals, home care providers, long-term acute care hospitals and skilled nursing facilities). We serve the federal government as well as a number of city and state governments providing management and maintenance of emergency equipment stockpiles, and we are an outsourced service provider to medical device manufacturers supporting critical device remediation and repair services. We deliver our solutions through our nationwide network of more than 150 service centers and 7 ISO 13485 Certified Centers of Excellence, among which we employ a team of more than 700 specialized biomed repair technicians, more than 4,000 field-based service operators who work onsite within customer facilities or in our local service centers, and over 200 field sales and account managers. Our fees are primarily paid directly by our customers rather than by direct reimbursement from third-party payors, such as private insurers, Medicare or Medicaid.

We deploy our solution offering across three primary service lines:

On-Site Managed Services: Onsite Managed Services are comprehensive programs that assume full responsibility for the management, reprocessing and logistics of medical equipment at individual facilities and integrated delivery networks (“IDNs”), with the added benefit of enhancing equipment utilization and freeing more clinician time for patient care. This solution monitors and adjusts equipment quantities and availability to address fluctuations in patient census and acuity. Our more than 1,600 onsite employees work 24/7 in customer facilities, augmenting clinical support by integrating proven equipment management processes, utilizing our proprietary management software and conducting daily rounds and unit-based training to ensure equipment is being used and managed properly, overall helping to optimize day-to-day operations and care outcomes. We assume full responsibility for ensuring equipment is available when and where it is needed, removing equipment when no longer in use, and decontaminating, testing and servicing equipment as needed between each patient use. Revenue attributable to such customers represented 23.8% and 27.9% of our total revenue for the three months ended September 30, 2022 and 2021, respectively, and 23.5% and 30.5% of our total revenue for the nine months ended September 30, 2022 and 2021, respectively.

20

Clinical Engineering Services: Clinical Engineering Services provides maintenance, repair and remediation solutions for all types of medical equipment, including general biomedical equipment, diagnostic imaging equipment and surgical equipment through supplemental and outsourced offerings. Our supplemental offering helps customers manage their equipment repair and maintenance backlog, assist with remediation and regulatory reporting and temporarily fill open biotechnical positions. With our outsourced offering, we assume full management, staffing and clinical engineering service responsibilities for individual or system-wide customer sites. The outsourced model deploys a dedicated, on-site team to coordinate the management of customer-owned equipment utilizing our proprietary information systems, third party vendors of services and parts, and a broad range of professional services for capital equipment planning and regulatory compliance. We leverage more than 700 technical resources from our over 150 local market service centers and 7 Centers of Excellence to flex staff in and out of customer facilities on an as-needed basis, ensuring customers pay only for time spent directly servicing their equipment by an appropriately qualified technician. We use flex staffing for our supplemental clinical engineering solution and to augment support when additional technicians are needed to supplement our outsourced services during peak workload. We contract our Clinical Engineering Services with acute care and alternate site facilities across the U.S., as well as with the federal government and any medical device manufacturers that require a broad logistical footprint to support their large-scale service needs. Revenue attributable to such customers represented 38.2% and 42.5% of our total revenue for the three months ended September 30, 2022 and 2021, respectively, and 37.0% and 38.5% of our total revenue for the nine months ended September 30, 2022 and 2021, respectively.

Equipment Solutions: Equipment Solutions primarily provides supplemental, peak need and per-case rental of general biomedical, specialty, and surgical equipment to acute care hospitals and alternate site providers in the U.S., including some of the nation’s premier healthcare institutions and integrated delivery networks. We contract for Equipment Solutions services directly with customers or through our contractual arrangements with hospital systems and alternate site providers. We consistently achieve high customer satisfaction ratings by delivering patient-ready equipment within our contracted equipment delivery times and by providing technical support and educational in-servicing for equipment as-needed in clinical departments, including the emergency room, operating room, intensive care, rehabilitation and general patient care areas. We are committed to providing the highest quality of equipment to our customers, and we do so through the use of our comprehensive Quality Management System which is based on the quality standards recognized worldwide for medical devices: 21 CFR 820 and ISO 13485:2016. This commitment ensures that customers have access to patient-ready equipment with the confidence of knowing it has been prepared and maintained to the highest industry standard to deliver optimal patient safety and outcomes. Revenue attributable to such customers represented 38.0% and 29.6% of our total revenue for the three months ended September 30, 2022 and 2021, respectively, and 39.5% and 31.0% of our total revenue for the nine months ended September 30, 2022 and 2021, respectively.

Many of our customers have multiple contracts and have revenue reported in multiple service lines. Our contracts vary based upon service offering, including with respect to term (with most being multi-year contracts), pricing (daily, monthly and fixed fee arrangements) and termination (termination for convenience to termination for cause only). Many of our contracts contain customer commitment guarantees and annual price increases tied to the consumer price index. Standard contract terms include payment terms, limitation of liability, force majeure provisions and choice of law/venue.

Further, the infrastructure and capabilities required to provide connected, responsive equipment lifecycle management is typically cost-prohibitive, even for large IDNs. Our nationwide network of clinical engineers, storage and repair facilities, vehicles and analytics tools gives us scale to provide cost-effective services for individual facilities, systems, regional IDNs, governments and device manufacturers.

Impact of COVID-19 on our Business

We have taken proactive action to protect the health and safety of our employees, customers, partners and suppliers. There continues to be uncertainty related to the full extent of the impact of the COVID-19 outbreak on our future results, but we believe our business model and our available borrowings under our Revolving Credit Facility position us well to continue to manage our business through this crisis.

We continue to monitor the evolving situation and guidance from federal, state and local public health authorities and may take additional actions based on their recommendations. In these circumstances, there may be developments outside our control requiring us to adjust our operating plan. As such, given the nature of this situation, we cannot reasonably estimate the future impacts of COVID-19 on our financial condition, results of operations or cash flows.

21

Initial Public Offering

On April 22, 2021, our registration statement on Form S-1 (File No. 333-253947) related to our initial public offering (“IPO”) was declared effective by the SEC, and our common stock began trading on the New York Stock Exchange (“NYSE”) on April 23, 2021. Our IPO closed on April 27, 2021.

RESULTS OF OPERATIONS

The following discussion addresses:

•our financial condition as of September 30, 2022; and

•the results of operations for the three and nine-month periods ended September 30, 2022 and 2021.

This discussion should be read in conjunction with the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q and the Management’s Discussion and Analysis of Financial Condition and Results of Operations sections included in our 2021 Form 10-K Report.

The following tables provide our results of operations for the three and nine months ended September 30, 2022 and 2021:

	Three Months Ended September 30,
(in thousands)	2022				2021				$		%
Consolidated Statement of Operations Data:			% of total revenue				% of total revenue
Revenue	$	271,185	100.0	%	$	262,424	100.0	%	$	8,761	3.3	%
Cost of revenue	169,582		62.5		158,990		60.6		10,592		6.7
Gross margin	101,603		37.5		103,434		39.4		(1,831)		(1.8)
Selling, general and administrative expense	86,044		31.7		75,052		28.6		10,992		14.6
Operating income	15,559		5.8		28,382		10.8		(12,823)		(45.2)
Interest expense	12,531		4.6		10,711		4.1		1,820		17.0
Tax indemnification expense	11,918		4.4		—		—		11,918		100.0
Income (loss) before income taxes and noncontrolling interest	(8,890)		(3.2)		17,671		6.7		(26,561)		(150.3)
Income tax (benefit) expense	(10,879)		(4.0)		7,943		3.0		(18,822)		(237.0)
Consolidated net income	$	1,989	0.8		$	9,728	3.7		$	(7,739)	(79.6)

22

	Nine Months Ended September 30,
(in thousands)	2022				2021				$		%
Consolidated Statement of Operations Data:			% of total revenue				% of total revenue
Revenue	$	839,613	100.0	%	$	748,212	100.0	%	$	91,401	12.2	%
Cost of revenue	516,218		61.5		444,346		59.4		71,872		16.2
Gross margin	323,395		38.5		303,866		40.6		19,529		6.4
Selling, general and administrative expense	254,303		30.3		225,334		30.1		28,969		12.9
Operating income	69,092		8.2		78,532		10.5		(9,440)		(12.0)
Loss on extinguishment of debt	1,418		0.2		10,116		1.4		(8,698)		(86.0)
Interest expense	34,456		4.1		40,444		5.4		(5,988)		(14.8)
Tax indemnification expense	11,918		1.4		—		—		11,918		100.0
Income before income taxes and noncontrolling interest	21,300		2.5		27,972		3.7		(6,672)		(23.9)
Income tax (benefit) expense	(5,672)		(0.7)		13,832		1.8		(19,504)		(141.0)
Consolidated net income	$	26,972	3.2		$	14,140	1.9		$	12,832	90.7

Consolidated Results of Operations for the three months ended September 30, 2022 compared to the three months ended September 30, 2021

Total Revenue

The following table presents revenue by service solution for the three months ended September 30, 2022 and 2021:

	Three Months Ended September 30,				Change
(in thousands)	2022		2021		%
Equipment Solutions	$	103,103	$	77,707	32.7	%
Clinical Engineering	103,639		111,614		(7.1)
Onsite Managed Services	64,443		73,103		(11.8)
Total revenue	$	271,185	$	262,424	3.3	%

Total revenue for the three months ended September 30, 2022 was $271.2 million, compared to $262.4 million for the three months ended September 30, 2021, an increase of $8.8 million or 3.3%. Equipment Solutions revenue increased 32.7% primarily driven by an increase in revenue of approximately $39.0 million related to the Sizewise Acquisition which was partially offset by lower utilization of our medical equipment post-COVID. Clinical Engineering revenue decreased 7.1% primarily due to lower federal government contract revenue offset partially by new business growth. Finally, our Onsite Managed Services revenue decreased 11.8% primarily driven by lower revenue associated with the renewal of the federal government contract. See Note 15, Concentration, to the consolidated financial statements included in Part I, Item 1, of this Quarterly Report on Form 10-Q for additional information on the renewed federal government contract.

Cost of Revenue

Total cost of revenue for the three months ended September 30, 2022 was $169.6 million compared to $159.0 million for the three months ended September 30, 2021, an increase of $10.6 million or 6.7%. On a percentage of revenue basis, cost of revenue increased from 60.6% of revenue in 2021 to 62.5% in 2022. The increase as a percentage of revenue was driven primarily from the federal government contract renewal and lower utilization of our medical equipment post-COVID offset partially by lower depreciation expense of approximately $7.0 million.

Gross Margin

Total gross margin for the three months ended September 30, 2022 was $101.6 million, or 37.5% of total revenue, compared to $103.4 million, or 39.4% of total revenue, for the three months ended September 30, 2021, a decrease of $1.8

23

million or 1.8%. The decrease in gross margin as a percentage of revenue was primarily impacted by the federal government contract renewal and lower utilization of our medical equipment.

Selling, General and Administrative Expense

Selling, general and administrative expense increased $11.0 million, or 14.6%, to $86.0 million for the three months ended September 30, 2022 as compared to the same period of 2021. Selling, general and administrative expense as a percentage of total revenue was 31.7% and 28.6% for the three months ended September 30, 2022 and 2021, respectively. The increase was primarily due to the increases in costs and amortization expense related to the acquisition of Sizewise in 2021.

Interest Expense

Interest expense increased $1.8 million to $12.5 million for the three months ended September 30, 2022 as compared to the same period of 2021 primarily due to rising interest rates partially offset by lower debt balances.

Tax Indemnification Expense

Tax indemnification expense increased $11.9 million for the three months ended September 30, 2022 as compared to the same period of 2021 due solely to non-recurring expense incurred from the release of the indemnification asset related to the Sizewise Acquisition.

Income Taxes

Income taxes were a benefit of $10.9 million and expense of $7.9 million for the three months ended September 30, 2022 and 2021, respectively. Income tax benefit increased $18.8 million for the three months ended September 30, 2022 as compared to the same period of 2021. The increase is due to the release of the reserve and associated interest and penalties accrual related to the Sizewise Acquisition of $11.9 million and a reduction in pretax income.

Consolidated Net Income

Consolidated net income decreased $7.7 million to $2.0 million in the third quarter of 2022 as compared to the same period of 2021. The decrease in net income was impacted primarily by lower margins.

Consolidated Results of Operations for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021

Total Revenue

The following table presents revenue by service solution for the nine months ended September 30, 2022 and 2021:

	Nine Months Ended September 30,				Change
(in thousands)	2022		2021		%
Equipment Solutions	$	331,810	$	232,319	42.8	%
Clinical Engineering	310,850		287,860		8.0
Onsite Managed Services	196,953		228,033		(13.6)
Total revenue	$	839,613	$	748,212	12.2	%

24

Total revenue for the nine months ended September 30, 2022 was $839.6 million, compared to $748.2 million for the nine months ended September 30, 2021, an increase of $91.4 million or 12.2%. Equipment Solutions revenue increased 42.8% primarily driven by the an increase in revenue of approximately $120.0 million related to the Sizewise Acquisition, which was partially offset by lower utilization of our medical equipment post-COVID. Clinical Engineering revenue increased 8.0% primarily due to new business growth offset partially by lower federal government revenue. Finally, our Onsite Managed Services revenue decreased 13.6% primarily driven by lower revenue associated with the renewal of the federal government contract.

Cost of Revenue

Total cost of revenue for the nine months ended September 30, 2022 was $516.2 million compared to $444.3 million for the nine months ended September 30, 2021, an increase of $71.9 million or 16.2%. On a percentage of revenue basis, cost of revenue increased from 59.4% of revenue in 2021 to 61.5% in 2022. The increase as a percentage of revenue was driven primarily by the federal government contract renewal and lower utilization of our medical equipment post-COVID partially offset by lower depreciation expense of approximately $15.0 million.

Gross Margin

Total gross margin for the nine months ended September 30, 2022 was $323.4 million, or 38.5% of total revenue, compared to $303.9 million, or 40.6% of total revenue, for the nine months ended September 30, 2021, an increase of $19.5 million or 6.4%. The decrease in gross margin as a percentage of revenue was primarily impacted by the federal government contract renewal, lower utilization of our equipment, and the acquisitions completed in the prior year.

Selling, General and Administrative Expense

Selling, general and administrative expense increased $29.0 million, or 12.9%, to $254.3 million for the nine months ended September 30, 2022 as compared to the same period of 2021. Selling, general and administrative expense as a percentage of total revenue was 30.3% and 30.1% for the nine months ended September 30, 2022 and 2021, respectively. The increase was primarily due to the increases in costs and amortization expense related to the acquisition of Northfield and Sizewise in 2021, partially offset by the elimination of the management services agreement with our majority owner.

Loss on Extinguishment of Debt

Loss on extinguishment of debt for the nine months ended September 30, 2022 was $1.4 million, compared to $10.1 million for the nine months ended September 30, 2021, a decrease of $8.7 million or 86.0%. Loss on extinguishment of debt for the nine months ended September 30, 2022 consisted of the write-off of unamortized debt discount related to the paydown of our term loan. The loss in 2021 was the result of the write-off of the unamortized deferred financing cost and debt discount along with an additional 1% redemption price related to the repayment of our Second Lien Term Loan.

Interest Expense

Interest expense decreased $6.0 million to $34.5 million for the nine months ended September 30, 2022 as compared to the same period of 2021 primarily due to the repayment of our Second Lien Term Loan from the proceeds of the IPO in the second quarter of 2021 as well as the prepayment of $119.1 million on our First Lien Term Loan during the first six months of 2022, partially offset by rising interest rates.

Tax Indemnification Expense

Tax indemnification expense increased $11.9 million for the nine months ended September 30, 2022 as compared to the same period of 2021 due solely to non-recurring expense incurred from the release of the indemnification asset related to the Sizewise Acquisition.

Income Taxes

Income taxes were a benefit of $5.7 million and expense of $13.8 million for the nine months ended September 30, 2022 and 2021, respectively. The income tax benefit increased $19.5 million primarily due to the release of the reserve and associated interest and penalties accrual related to the Sizewise Acquisition of $11.9 million and benefit from stock options and stock compensation offset by the effect of pre-tax income from operations plus addbacks for non-deductible expenses related to executive compensation disallowed under Internal Revenue Code Section 162(m).

25

Consolidated Net Income

Consolidated net income increased $12.8 million to $27.0 million in the nine months ended September 30, 2022 as compared to the same period of 2021. The increase in net income was impacted by the 12.2% increase in revenue.

Adjusted EBITDA

Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”) was $225.2 and $245.8 million for the nine months ended September 30, 2022 and 2021, respectively. Adjusted EBITDA for the nine months ended September 30, 2022 was lower than in 2021 primarily due to the reduction in gross margin.

EBITDA is defined as earnings attributable to Agiliti, Inc. before interest expense, income taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA excluding non-cash share-based compensation expense, management fees and other non-recurring gains, expenses or losses, transaction costs, remeasurement of tax receivable agreement and loss on extinguishment of debt. In addition to using EBITDA and Adjusted EBITDA internally as measures of operational performance, we disclose them externally to assist analysts, investors and lenders in their comparisons of operational performance, valuation and debt capacity across companies with differing capital, tax and legal structures. We believe the investment community frequently uses EBITDA and Adjusted EBITDA in the evaluation of similarly situated companies. Adjusted EBITDA is also used by the Company as a factor to determine the total amount of incentive compensation to be awarded to executive officers and other employees. EBITDA and Adjusted EBITDA, however, are not measures of financial performance under GAAP and should not be considered as alternatives to, or more meaningful than, net income as measures of operating performance or to cash flows from operating, investing or financing activities or as measures of liquidity. Since EBITDA and Adjusted EBITDA are not measures determined in accordance with GAAP and are thus susceptible to varying interpretations and calculations, EBITDA and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. EBITDA and Adjusted EBITDA do not represent amounts of funds that are available for management’s discretionary use. EBITDA and Adjusted EBITDA presented below may not be the same as EBITDA and Adjusted EBITDA calculations as defined in the First Lien Credit Facilities. A reconciliation of net income attributable to Agiliti, Inc. to Adjusted EBITDA is included below:

	Nine Months Ended September 30,
(in thousands)	2022		2021
Net income attributable to Agiliti, Inc. and Subsidiaries	$	26,841	$	14,023
Interest expense	34,456		40,444
Income tax (benefit) expense (1)	(5,672)		13,832
Depreciation and amortization	133,711		138,676
EBITDA	189,336		206,975
Non-cash share-based compensation expense	15,066		10,127
Management and other expenses (2)	13,877		7,626
Transaction costs (3)	5,465		6,440
Tax receivable agreement remeasurement	—		4,542
Loss on extinguishment of debt (4)	1,418		10,116
Adjusted EBITDA	$	225,162	$	245,826
Other Financial Data:
Net cash provided by operating activities	$	161,901	$	138,413
Net cash (used in) investing activities	(58,298)		(481,462)
Net cash provided by (used in) financing activities	(145,717)		260,257

____________________

(1) Income tax (benefit) expense includes the $11.9 million tax benefit due to the release of the reserve and associated interest and penalties related to the Sizewise Acquisition.

(2) Management and other expenses includes (a) tax indemnification expense related to the Sizewise Acquisition; (b) management fees and buyout termination fee under the Advisory Services Agreement, which was terminated in connection with the initial public offering in 2021; and (c) non-recurring expenses.

26

(3) Transaction costs represent costs associated with potential and completed mergers and acquisitions and are primarily related to the Northfield and Sizewise acquisitions.

(4) Loss on extinguishment of debt for the nine months ended September 30, 2022 consists of the write-off of the unamortized debt discount related to the partial prepayment of the First Lien Term Loan. Loss on extinguishment of debt for the nine months ended September 30, 2021 consists of the write-off of the unamortized deferred financing costs and debt discount and an additional 1% redemption price related to the repayment of our Second Lien Term Loan and the write-off of the unamortized deferred financing cost related to the amendment of our Revolving Credit Facility.

SEASONALITY

Quarterly operating results are typically affected by seasonal factors. Historically, our first and fourth quarters are the strongest, reflecting increased customer utilization during the fall and winter months. However, COVID-19 has impacted the seasonality of our business.

LIQUIDITY AND CAPITAL RESOURCES

Our principal sources of liquidity are cash flows from operating activities and borrowings under our Revolving Credit Facility, which provides for loans in an amount of up to $250.0 million. Our principal uses of liquidity are to fund capital expenditures related to purchases of medical equipment, provide working capital, meet debt service requirements and finance our strategic plans.

We believe our existing balances of cash and cash equivalents, our currently anticipated operating cash flows and availability under our Revolving Credit Facility will be sufficient to meet our cash needs arising in the ordinary course of business for the next twelve months. If new financing is necessary, there can be no assurance that any such financing would be available on commercially acceptable terms, or at all. To date, we have not experienced difficulty accessing the credit market; however, future volatility in the credit market may increase costs associated with issuing debt instruments or affect our ability to access those markets. In addition, it is possible that our ability to access the credit market could be limited at a time when we would like, or need to do so, which could have an adverse impact on our ability to refinance debt and/or react to changing economic and business conditions.

Net cash provided by operating activities was $161.9 and $138.4 million for the nine months ended September 30, 2022 and 2021, respectively. Net cash provided by operating activities during 2022 was favorably impacted by the timing of collections on accounts receivables.

Net cash used in investing activities was $58.3 and $481.5 million for the nine months ended September 30, 2022 and 2021, respectively. The decrease in net cash used in investing activities was primarily due to the Northfield Acquisition completed on March 19, 2021.

Net cash used in financing activities was $145.7 million for the nine months ended September 30, 2022 compared to net cash provided by financing activities of $260.3 million for the nine months ended September 30, 2021. The change in net cash used in financing activities was primarily due to proceeds from the issuance of common stock from the IPO in 2021. In 2022, the change in net cash used in financing was driven by prepayment of the First Lien Term Loan of $119.1 million.

RECENT ACCOUNTING PRONOUNCEMENT

See Note 2, Recent Accounting Pronouncements, to the consolidated financial statements included in Part I, Item 1, of this Quarterly Report on Form 10-Q.

OFF-BALANCE SHEET ARRANGEMENTS

As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (“SPEs”), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of September 30, 2022, we did not have any unconsolidated SPEs.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Form 10-Q are forward-looking statements. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-

27

looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “will”, “should”, “can have”, “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including:

•effects from political and policy changes that could limit our growth opportunities;

•effects from the continued COVID-19 pandemic on our business and the economy;

•our potential inability to maintain existing contracts or contract terms with, or enter into new contracts with, our customers;

•cancellations by or disputes with customers;

•our potential failure to maintain our reputation, including by protecting intellectual property;

•effects of a global economic downturn on our customers and suppliers;

•a decrease in our customers’ patient census or services;

•competitive practices by our competitors that could cause us to lose market share, reduce our prices or increase our expenditures;

•the bundling of products and services by our competitors, some of which we do not offer;

•consolidation in the healthcare industry, which may lead to a reduction in the prices we charge;

•adverse developments with supplier relationships;

•the potential inability to change the manner in which healthcare providers traditionally procure medical equipment;

•our potential inability to attract and retain key personnel;

•our potential inability to make attractive acquisitions or successfully integrate acquire businesses;

•an increase in expenses related to our pension plan;

•the fluctuation of our cash flow;

•credit risks relating to home care providers and nursing homes;

•potential claims related to the medical equipment that we outsource and service;

•the incurrence of costs that we cannot pass through to our customers;

•a failure of our management information systems;

•limitations inherent in all internal controls systems over financial reporting;

•social unrest;

•our failure to keep up with technological changes;

•our failure to coordinate the management of our equipment;

•challenges to our tax positions or changes in taxation laws;

•litigation that may be costly to defend;

•uncertainty surrounding healthcare reform initiatives;

•federal privacy laws that may subject us to more stringent penalties;

•our relationship with healthcare facilities and marketing practices that are subject to federal Anti-Kickback Statute and similar state laws;

•our contracts with the federal government that subject us to additional oversight;

•the impact of changes in third-party payor reimbursement for healthcare items and services on our customers’ ability to pay for our services;

•the highly regulated environment our customers operate in; and

•potential recall or obsolescence of our large fleet of medical equipment.

We derive many of our forward-looking statements from our operating budgets and forecasts, which are based on many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q and elsewhere in our filings with the SEC. All written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements as well as other cautionary statements that are made from time to time in our other SEC filings and public communications. You should evaluate all forward-looking statements made in this Form 10-Q in the context of these risks and uncertainties.

We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. The forward-looking statements included in this Form 10-Q are made only as of the date hereof. We undertake no obligation to

28

update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to market risk arising from adverse changes in interest rates, fuel costs and pension valuation. We do not enter into derivatives or other financial instruments for speculative purposes.

Interest Rates

We use both fixed and variable rate debt as sources of financing. As of September 30, 2022, we had approximately $1,080.8 million of total debt outstanding before netting with deferred financing costs and unamortized debt discount, of which $556.9 million was bearing interest at variable rates. Based on variable debt levels at September 30, 2022, a 1.0 percentage point change in interest rates on variable rate debt would have resulted in annual interest expense increasing by approximately $5.6 million.

Fuel Costs

We are exposed to market risks related to changes in the price of gasoline used to fuel our fleet of delivery and sales vehicles. A hypothetical 10% increase in the first nine months of 2022 average price of unleaded gasoline, assuming gasoline usage levels for the nine months ended September 30, 2022, would lead to an increase in fuel costs of approximately $0.6 million.

Pension

Our pension plan assets, which were approximately $26.4 million at December 31, 2021, are subject to volatility that can be caused by fluctuations in general economic conditions. Continued market volatility and disruption could cause declines in asset values, and if this occurs, we may need to make additional pension plan contributions and our pension expense in future years may increase. A hypothetical 10% decrease in the fair value of plan assets at December 31, 2021 would lead to a decrease in the funded status of the plan of approximately $2.6 million.

Other Market Risk

As of September 30, 2022, we have no other material exposure to market risk.

Item 4. Controls and Procedures

i.Evaluation of disclosure controls and procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2022.

ii.Changes in internal control over financial reporting

There was no change in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The Company, in the ordinary course of business, is subject to liability claims related to employees and the equipment that it rents and services. Asserted claims are subject to many uncertainties and the outcome of individual matters is not predictable. While the ultimate resolution of these actions may have an impact on the Company’s financial results for a particular reporting period, management believes that any such resolution would not have a material adverse effect on the financial position, results of operations or cash flows of the Company and the chance of a negative outcome on outstanding litigation is considered remote. See the additional information in Note 11, Commitments and Contingencies, to the consolidated financial statements included in Part I, Item 1 of the Quarterly Report on Form 10-Q.

29

Item 1A. Risk Factors

There have been no material changes to the risk factors disclosed under the heading “Risk Factors” in our 2021 Form 10-K Report under Part I, Item 1A for the quarter ended September 30, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

30

Item 6. Exhibits

Exhibit Number	Description
31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	The cover page for the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101.

____________________

*    Furnished, not filed.

31

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 10, 2022

Agiliti, Inc.
By	/s/ Thomas J. Leonard
Thomas J. Leonard
Chief Executive Officer
(Principal Executive Officer and Duly Authorized Officer)
By	/s/ James B. Pekarek
James B. Pekarek
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

32